The Story Began: Preemies, Prevention, Progesterone (17P): My First Preemie
The Story Continued: Preemies, Prevention, Progesterone (17P): My Second Pregnancy
The Story Continued: Preemies, Prevention, Progesterone (17P): Review of the Medical Literature
I was so afraid of having another preemie born at 33 weeks gestation, that I tried to make the best educated decision I could for my second pregnancy, and agreed to a relatively new treatment of weekly 17P injections, in hopes that the clinical studies were correct: 17P has been shown as safe and effective in preventing recurrent spontaneous preterm labor.
This decision was weighed with the knowledge that potential risks of 17P have not been disproven, as the U.S. Food and Drug Administration (FDA) has not approved this treatment for the specific use of preventing recurring preterm labor, although it has been shown as safe and effective for other conditions. 17P is not approved for use in pregnancy, as the exact dosage has not yet been determined by the FDA. However, my doctor, as well as the clinical studies I consulted, thoroughly explained the efficacy of 17P treatment as it significantly reduced the risk of delivery at less than 37 weeks gestation.
For me, the risk of another premature baby born before 34 weeks gestation (and all of the potential long-term health risks) were too high compared to the potential benefits of treatment.
After making my decision, the only hurdle left for me: I have a slightly irrational fear of needles. How am I going to receive a weekly injection, into the muscle, while I am hugely pregnant and already over-sensitive?